Ann: Nyrada Quarterly Activities Report & Appendix 4C, page-19

My post said or implied nothing nothing about a jv with Walter Reed Medica Centre nor any funding from WR for the current study. Merely indicated if the WR results are positive ( by that I mean it confirms what NYR observed) then that could open doors to secure some funding from other interested parties for the further studies ( Phase 1, phase 2 etc) rather than be solely dependent on a CR for funding. If the WR study yields a confirmatory result it will not go un-noticed by big pharma, venture capital , etc given WR's credibility and pre-emience in the neurology field. Am pretty sure that the ASX company Neuren, a massive multibagger, also ran trials with WR in the early days. And dont downplay the fact that so far our initial study and that of WR currently uses the "rat model", WR know what they are doing and this model has been refined to a point its now a well established route in the early trialling stages before moving to human trials